Steatohepatitis Stocks List

Steatohepatitis Stocks Recent News

Date Stock Title
Oct 2 IONS IONS' Rare Neurology Disorder Candidate Gets FDA's Fast Track Tag
Oct 2 VKTX Weight loss drug breakthroughs, gene therapies, and more: 8 clinical trials to watch right now
Oct 1 IONS Ionis gets U.S. FDA fast track designation for its Alexander disease treatment
Oct 1 SGMT Sagimet soars on FDA breakthrough therapy designation for its liver disease treatment
Oct 1 IONS Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease
Oct 1 SGMT Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH
Oct 1 SGMT Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 30 VKTX Why Viking Therapeutics Stock Topped the Market Today
Sep 30 GALT Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference
Sep 30 AKRO Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference
Sep 29 VKTX Is Viking Therapeutics Stock a Buy?
Sep 29 VKTX Is Viking Therapeutics, Inc. (VKTX) the Best Performing Long Term Stock in 2024?
Sep 28 VKTX Better Rising Biotech: Viking Therapeutics vs. Summit Therapeutics
Sep 27 VKTX Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know
Sep 27 VKTX Is Viking Therapeutics Inc. (VKTX) the Best Performing Small-Cap Stock in 2024?
Sep 26 BLTE Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
Steatohepatitis

Steatohepatitis is a type of fatty liver disease, characterized by inflammation of the liver with concurrent fat accumulation in liver. Mere deposition of fat in the liver is termed steatosis, and together these constitute fatty liver changes.There are two main types of fatty liver disease: alcohol-related fatty liver disease and non-alcoholic fatty liver disease (NAFLD). Risk factors for NAFLD include diabetes, obesity and metabolic syndrome. When inflammation is present it is referred to as alcoholic steatohepatitis and nonalcoholic steatohepatitis (NASH). Steatohepatitis of either cause may progress to cirrhosis, and NASH is now believed to be a frequent cause of unexplained cirrhosis (at least in Western societies). NASH is also associated with lysosomal acid lipase deficiency.The word is from steato-, meaning "fat" and hepatitis, meaning "inflammation of the liver".

Browse All Tags